BARDA to invest up to $1.2B in AstraZeneca COVID-19 vaccine | J&J stops shipping talc baby powder in US, Canada | FDA issues warning letters about breast implants
May 21, 2020
Aon Life Sciences Advisor
SIGN UP ⋅   SHARE
Top Stories
The Biomedical Advanced Research and Development Authority will fund up to $1.2 billion to help AstraZeneca develop, produce and distribute a COVID-19 vaccine created by the University of Oxford. AstraZeneca has licensed the vaccine, called AZD1222, from Oxford and distribution could begin as early as this fall.
Full Story: BioPharma Dive (5/21) 
LinkedIn Twitter Facebook Email
Liability and Safety
Johnson & Johnson is terminating distribution of talc-based baby powder in the US and Canada but is continuing to distribute the product elsewhere. J&J has been repeatedly sued by consumers claiming concealment of cancer risk in the product.
Full Story: BNN Bloomberg (Canada) (5/19) 
LinkedIn Twitter Facebook Email
The FDA issued a warning letter to Allergan, saying the company did not recruit enough participants or collect enough safety data in studies of its breast implants. A warning letter also was sent to Ideal Implant over the company's manufacturing practices.
Full Story: FierceBiotech (5/15) 
LinkedIn Twitter Facebook Email
Business and Market Trends
Patients who take hydroxychloroquine for lupus and rheumatoid arthritis are afraid they will not be able to get the treatment after President Donald Trump announced he was taking it to help ward off COVID-19. A shortage occurred when Trump mentioned the drug as a potential COVID-19 treatment earlier this year.
Full Story: KYW-TV (Philadelphia) (5/19),  WBUR-FM (Boston) (5/19) 
LinkedIn Twitter Facebook Email
Government and Regulatory
Health Care and Policy
The NIH is allowing adaptive clinical trials instead of randomized, double-blind, placebo-controlled studies to accelerate the development of treatments and vaccines for COVID-19. Adaptive trials are usually faster and less expensive than conventional clinical trials by allowing changes to objectives, participant pools and methods based on early results, and an adaptive trial led researchers to discard hydroxychloroquine in favor of remdesivir, which will now be the comparator drug for baricitinib in COVID-19 patients.
Full Story: Los Angeles Times (tiered subscription model) (5/18) 
LinkedIn Twitter Facebook Email
Company and Financial News
Gilead Sciences plans to donate 940,000 doses of the experimental COVID-19 drug remdesivir to the federal government for distribution to US hospitals, up from 607,000 announced previously, according to an HHS spokesperson. The additional doses could treat 30,000 to 55,000 more patients, depending on how many doses each patient is given.
Full Story: STAT (tiered subscription model) (5/18) 
LinkedIn Twitter Facebook Email
News from Aon
Stuck In The Middle: Stress and 'The Sandwich Generation'
Stuck In The Middle: Stress and ‘The Sandwich Generation’ With worries that go beyond typical anxieties over the wellbeing of children and parents, members of the Sandwich Generation are likely to feel burdened by the financial stress of caring for both. Learn More.
LinkedIn Twitter Facebook Email
Aon's COVID-19 Insights & Resources
The global outbreak of the novel coronavirus (COVID-19) has created unprecedented challenges. Aon has developed a resource site to help business leaders implement effective responses to the impact of the pandemic on businesses, employees and communities. These insights can help readers make better decisions in these complex and volatile times. Learn more and view the COVID-19 Response Site.
LinkedIn Twitter Facebook Email
LEARN MORE ABOUT :
Aon Home Page  |    Aon Life Sciences
Thought Leadership  |    Media Room
It is never too late to be wise.
Daniel Defoe,
writer, journalist
LinkedIn Twitter Facebook Email
About Aon Life Sciences Practice
Aon provides Life Sciences companies with end-to-end risk solutions, supporting organizations from the initial discovery phase to final product launch. The practice provides solutions across the Life Sciences for pharmaceutical manufacturers; generic and OTC pharmaceutical companies; biotechnology and biopharmaceutical companies; genomic and proteomic companies; drug delivery system; diagnostic substance companies; and medical device and equipment manufacturers.

Contact Aon
Aon Risk Solutions – Life Sciences
James Walters, Global Practice Leader
+1.215.255.1795
james.walters@aon.com
www.aon.com

 Linkedin Twitter
About Aon
Aon plc (NYSE:AON) is a leading global professional services firm providing a broad range of risk, retirement and health solutions. Our 50,000 colleagues in 120 countries empower results for clients by using proprietary data and analytics to deliver insights that reduce volatility and improve performance.
SmartBrief publishes more than 200 free industry newsletters - Browse our portfolio
Unsubscribe  |    Privacy policy
CONTACT US: FEEDBACK  |    ADVERTISE
Powered By SmartBrief
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004